Les renseignements du Formulaire de médicaments s’adressent aux professionnels de la santé. Il ne s’agit pas d’un avis médical. Certains des renseignements, y compris ceux sur le financement des médicaments anticancéreux, ne s’appliquent pas à tous les patients. Les plans de traitement du cancer sont propres à chaque patient. Si vous êtes un patient, veuillez parler avec votre équipe soignante pour comprendre comment ces renseignements s’appliquent à vous.
tamoxifen
Tamoxifen is a synthetic non-steroidal anti-estrogenic analog. It is thought to competitively block estrogen receptors and suppress the genome of the breast cancer cell. It also has low affinity to the androgen receptor. Tamoxifen displays estrogenic-like effects on several body systems including the endometrium, bone and blood lipids, and may have growth inhibitory effects that are not anti-estrogenic. Tamoxifen increases the risk of endometrial cancer, uterine sarcoma, arterial and venous thromboembolism and is not approved for use in Canada to prevent breast cancer. Requires activation to endoxifen; patients taking concomitant medications that inhibit CYP2D6 or with certain polymorphisms of CYP2D6 may have subtherapeutic levels.
Steady state of tamoxifen is generally reached after 3-4 weeks.
High concentrations in uterus, endometrium, breast tissues, distribution also observed in lung, liver, kidneys, and pancreas.
| Cross blood brain barrier? | Higher levels of tamoxifen and metabolites observed in brain metastases than normal brain tissue |
| PPB | >98% |
Prodrug, requires activation to endoxifen. Metabolized by CYP2D6 or 3A4 pathways to 4-hydroxytamoxifen or N-desmethyltamoxifen, then to endoxifen. CYP2B6, 2C8, 2C9, and 2C19 play a minor role. Tamoxifen is an inhibitor of p-glycoprotein. Autoinduction has been described.
| Active metabolites | N-desmethyltamoxifen, 4-hydroxytamoxifen, endoxifen |
| Inactive metabolites | Yes |
Secreted in bile, undergoes enterohepatic circulation, 65% of the dose slowly excreted in feces over 2 weeks, mainly as polar conjugates.
| Urine | 9 to 13% |
| Half-life |
Parent drug: 5-7 days |
- Adjuvant treatment of breast cancer (estrogen receptor positive tumours) in women
- Treatment of hormone responsive locally advanced or metastatic breast cancer in women
Other Uses:
- Gynecological cancers (endometrial, ovarian)
- Desmoid tumours
Emetogenic Potential:
Extravasation Potential: Not applicable
| ORGAN SITE | SIDE EFFECT* (%) | ONSET** | |||
|---|---|---|---|---|---|
| Cardiovascular | Arterial thromboembolism (<10%) | D | |||
| Venous thromboembolism (<10%) | D | ||||
| Dermatological | Alopecia (<10%) | E | |||
| Other (porphyria cutanea tarda, cutaneous lupus erythematosus - rare) | E | ||||
| Radiation recall reaction (rare) | I | ||||
| Rash (>10%; in rare cases may be severe) | E | ||||
| Gastrointestinal | Constipation (<10%) | E | |||
| Diarrhea (<10%) | E | ||||
| Nausea, vomiting (>10%) | I | ||||
| General | Edema , fluid retention (>10%) | E | |||
| Fatigue (>10%) | I E D | ||||
| Tumour flare (<10%) (rare ↑ calcium early in therapy) | E | ||||
| Hematological | Myelosuppression (<1%, usually mild, including platelets) | E | |||
| Hepatobiliary | ↑ LFTs (<10%, rarely severe) | D | |||
| Pancreatitis (rare) | E | ||||
| Hypersensitivity | Hypersensitivity (<10%) | I | |||
| Metabolic / Endocrine | ↑ Ca | I E | |||
| ↑ Triglycerides (<10%) | D | ||||
| Musculoskeletal | Musculoskeletal pain (<10%) | E | |||
| Neoplastic | Secondary malignancy (including endometrial cancer, uterine sarcoma - rare) | D | |||
| Nervous System | Depression (<1%) | D | |||
| Dizziness (<10%) | E | ||||
| Dysgeusia (<1%) | I | ||||
| Headache (<10%) | E | ||||
| Optic neuritis (<1%) | D | ||||
| Paresthesia (<10%) | E | ||||
| Ophthalmic | Cataract (<10%) | D | |||
| Eye disorders (corneal changes - rare) | D | ||||
| Retinopathy (<10%) | D | ||||
| Reproductive and breast disorders | Endometrial hyperplasia , polyps (<10%) | D L | |||
| Estrogen deprivation symptoms (>10%) | E | ||||
| Irregular menstruation | D | ||||
| Other (ovarian cysts, uterine fibroids, vaginal polyps: <10%) | D L | ||||
| Vaginal bleeding or discharge (>10%) | E | ||||
| Respiratory | Pneumonitis (rare) | D | |||
| Vascular | Vasculitis (cutaneous; rare) | E | |||
* "Incidence" may refer to an absolute value or the higher value from a reported range.
"Rare"
may refer to events with < 1% incidence, reported in post-marketing, phase 1 studies,
isolated data or anecdotal
reports.
** I = immediate (onset in hours to days)
E = early (days to weeks)
D = delayed (weeks to months)
L = late (months to years)
Tamoxifen is usually well-tolerated and serious side effects are rare. The most frequent side effects are hot flashes, nausea and vomiting. These may occur in up to 25% of patients and are rarely severe enough to discontinue treatment. Patients who have their sleep interrupted by drenching night sweats may benefit by taking tamoxifen in the morning. Clonidine (0.1mg daily), venlafaxine (75 mg daily) and gabapentin (titrated to 300 mg TID) have been shown to help reduce the number of hot flashes in some studies.
In some patients, a transient increase in bone pain, local disease flare (swelling and redness) and/or hypercalcemia may occur at the initiation of therapy in patients with metastatic disease (tamoxifen flare response). Treatment should continue for a minimum of 3 to 4 weeks to rule out tumour flare response. Serum calcium should be monitored for a few weeks, starting 3-7 days after starting treatment in patients with extensive bony metastatic disease.
The risk of endometrial cancer increases following tamoxifen therapy and may be related to the estrogen-like effect of tamoxifen. An increase in uterine sarcomas was also reported in prevention trials. Pelvic complaints, such as unusual vaginal bleeding, unusual pelvis pain/pressure should be promptly evaluated in patients taking tamoxifen.
Decreases in platelets (usually to 80-90 x 109/L) or leukocytes have been observed, but no bleeding has been reported. In clinical trials, the incidence of myalgia was similar between patients treated with tamoxifen or an aromatase inhibitor.
Tamoxifen is associated with increased rates of thromboembolic events, including stroke, deep vein thrombosis, pulmonary embolism, and microvascular thrombosis after breast reconstruction surgery. Higher rates of complications were observed in a retrospective study with patients who were taking tamoxifen within 28 days of delayed breast reconstruction, which included total flap loss due to either venous or arterial thrombosis.
Ocular problems (retinopathy, cataracts, corneal opacities, optic neuritis) have been reported in patients.
Radiation recall reaction was usually reversible when tamoxifen was held, and milder upon re-challenge. Treatment with tamoxifen was continued in most cases.
Refer to protocol by which patient is being treated. Patients with advanced disease are usually treated until progression, and patients being treated with adjuvant intent for 5 years.
Oral: 20 - 40 mg daily in single or divided doses
|
Toxicity
|
Action
|
|
Severe estrogen depletion symptoms
|
Consider short drug holiday and rechallenge |
|
Arterial/Venous thromboembolism
|
Discontinue
|
|
Severe depression
|
Discontinue
|
|
Pancreatitis, pneumonitis, hepatotoxicity, severe hypercalcemia |
Discontinue
|
|
Cataracts, retinopathy, corneal changes, severe myalgia |
Consider discontinuing
|
|
Severe skin symptoms, porphyria cutanea tarda, cutaneous lupus erythematosus |
Discontinue
|
| Microvascular breast reconstruction | Consider temporary hold |
Adjustment required, no details found
No adjustment required
No adjustment required.
Not recommended as safety and efficacy have not been established.
- Oral self-administration; drug available by outpatient prescription.
- Swallow whole with a glass of water, with or without food.
- Do not crush or chew the tablets.
- Take the dose at about the same time each day.
- Patients with hypersensitivity to tamoxifen or any of its components.
- Use with extreme caution in patients with a history of significant thromboembolic disease.
- Some brands of tamoxifen contain lactose; carefully consider use in patients with hereditary galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption.
- Use with caution in patients with pre-existing myelosuppression or depression.
- Consider temporary hold in patients undergoing delayed microvascular breast reconstruction.
- Tiredness and weakness have been reported. Caution when driving and operating machinery while such symptoms persist.
Other Drug Properties:
-
Carcinogenicity:
Documented in animals
-
Genotoxicity:
Documented in animals
-
Embryotoxicity:
Likely
Changes similar to those seen with DES have been reported in models of fetal development
-
Fetotoxicity:
Likely
Tamoxifen is not recommended for use in pregnancy. Adequate contraception should be used by both sexes during treatment, and for 9 months after the last dose.
-
Excretion into breast milk:
Unknown
Breastfeeding is not recommended.
-
Fertility effects:
Unknown
Tamoxifen is a substrate of CYP 3A (major), 2D6 (major), 2C8/9, 2C19, 2B6. Inducers (and inhibitors) of these enzymes can theoretically increase (and decrease) the metabolism of tamoxifen and the formation of its metabolites.
| AGENT | EFFECT | MECHANISM | MANAGEMENT |
|---|---|---|---|
| Oral anticoagulants (e.g : warfarin) | ↑ Significant increase in anticoagulant effect | Unknown | Monitor prothrombin time; adjust anticoagulant dose as required |
| Thyroid function test | ↑ T4 (thyroxine) | ↑ thyroxine-binding globulin | None, thyroid function does not appear to be affected |
| Drugs metabolized by P450 oxidases or p-glycoprotein | Altered effects; ↓ metabolism of enzyme substrates | Tamoxifen inhibits P450 oxidases or p-glycoprotein | Caution |
| Mitomycin | ↑ risk of hemolytic uremic syndrome | Unknown | Avoid concomitant use |
| Bromocriptine | Potentially ↑ side effects of tamoxifen | ↑ serum levels of tamoxifen and metabolites | Caution |
| Drugs prolonging QT | Prolongation of QT | Possible additive effects with tamoxifen | Avoid concomitant use |
| CYP3A4 inducers (i.e. phenytoin, rifampin, dexamethasone, carbamazepine, phenobarbital, St. John’s Wort, etc) | ↓ effects of tamoxifen | ↑ metabolism | Caution |
| Other drugs metabolised by CYP 3A4 | ↓ effect of CYP3A4 substrates | Tamoxifen may induce CYP 3A4 | Avoid concomitant use |
| Anastrozole | ↓ concentrations of anastrozole (27%) | Unknown | Do not co-administer since no efficacy or safety benefit |
| Letrozole | ↓ plasma concentrations of letrozole (38%) | Unknown | Avoid concomitant usage as no efficacy or data available |
| Potent CYP2D6 inhibitors (i.e. fluoxetine, paroxetine, quinidine, pimozide, perphenazine, terbinafine, etc) | ↓ plasma concentration of tamoxifen active metabolite | Inhibits CYP2D6 metabolism of tamoxifen | Avoid concomitant use |
| Moderate CYP 2 D6 inhibitors (i.e. desipramine, haloperidol, citalopram, sertraline, hydroxyzine, amlodipine, ritonavir) | ↓ plasma concentration of tamoxifen active metabolite | Inhibits CYP2D6 metabolism of tamoxifen | Caution, consider alternative drug options |
| Low CYP 2D6 activity (in patients with certain CYP2D6 alleles) | ↓ plasma concentration of tamoxifen active metabolite | Inhibits CYP2D6 metabolism of tamoxifen | Monitor treatment response; routine pharmacogenomics screening is currently not recommended |
Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.
| Monitor Type | Monitor Frequency |
|---|---|
| Calcium, in patients with extensive bone metastases; for first few weeks then periodic | |
Clinical assessment of toxicity - vaginal bleeding, ocular, thromboembolism, myalgia, tumour flare, GI and pulmonary effects, rash, etc. |
At each visit |
Grade toxicity using the current NCI-CTCAE (Common Terminology Criteria for Adverse Events) version
| Monitor Type | Monitor Frequency |
|---|---|
CBC |
Baseline and periodic |
Triglycerides and cholesterol in patients with pre-existing hyperlipidemia |
Baseline and periodic |
Boekhout AH, Vincent AD, Dalesio OB. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: A randomized double-blind, placebo controlled trial. J Clin Oncol 2011;29(29):3862-8.
Bordeleau L, Pritchard KI, Loprinzi CL, et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J Clin Oncol 2010;28(35):5147-52.
Borges S, Desta Z, Li L, Skaar TC, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80(1):61-74.
Cancer Drug Manual (the Manual): Tamoxifen. British Columbia Cancer Agency (BCCA), May 2010.
Lien EA, Wester K, Lonning PE, et al. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 1991;63:641-5.
Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Research 1991;51:4837-44.
Loprinzi CL, Kugler JW, Barton DL, et al. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 2007;25(3):308-12.
McEvoy GK, editor. AHFS Drug Information 2011. Bethesda: American Society of Health-System Pharmacists, p. 1231-38.
Montes A, Powles TJ, O'Brien ME, et al. A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome. Eur J Cancer 1993;29A(13):1854-7.
Pandya KJ, Morrow GR, Roscoe JA, et a. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;66(9488):818-24.
Prescribing information: Novaldex® (tamoxifen). AstraZeneca Pharmaceuticals (US)., September 27, 2005.
Product Monograph: Novaldex-D® (tamoxifen). AstraZeneca Canada Inc., December 2021.
Product Monograph: Arimidex® (anastrozole). AstraZeneca Canada, Inc., April 27, 2011.
Product Monograph: Femara® (letrozole). Novartis Pharmaceuticals Canada Inc., January 23, 2012.
Product Monograph: Tamofen® (tamoxifen). Sanofi-aventis Canada Inc., May 31, 2006.
Sideras K, Ingle JN, Ames MM, et al. Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 2010: 28; 2768-2776.
May 2022 Updated Pregnancy/lactation section
Refer to the New Drug Funding Program or Ontario Public Drug Programs websites for the most up-to-date public funding information.
The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.
The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.
Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.
While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an “as-is” basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information’s quality, accuracy, currency, completeness, or reliability.
CCO and the Formulary’s content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person’s use of the information in the Formulary.